Marinus Pharmaceuticals (NASDAQ:MRNS) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued to investors on Thursday morning,Benzinga reports. The brokerage currently has a $4.00 target price on the biopharmaceutical company’s stock.

A number of other equities analysts also recently weighed in on MRNS. Truist Financial downgraded shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. LADENBURG THALM/SH SH cut shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. Jefferies Financial Group reiterated a “hold” rating and set a $0.50 price target (down previously from $5.00) on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. HC Wainwright reissued a “neutral” rating and set a $2.00 price target on shares of Marinus Pharmaceuticals in a research report on Thursday. Finally, Oppenheimer raised Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a research report on Monday, September 23rd. Nine equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Marinus Pharmaceuticals has a consensus rating of “Hold” and an average target price of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of MRNS traded down $0.01 during midday trading on Thursday, hitting $0.30. The stock had a trading volume of 1,600,465 shares, compared to its average volume of 1,584,877. Marinus Pharmaceuticals has a twelve month low of $0.26 and a twelve month high of $11.26. The company has a 50 day simple moving average of $1.24 and a two-hundred day simple moving average of $1.32. The firm has a market cap of $16.71 million, a price-to-earnings ratio of -0.12 and a beta of 1.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.02. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 446.48%. The company had revenue of $8.54 million during the quarter, compared to analysts’ expectations of $8.95 million. Analysts forecast that Marinus Pharmaceuticals will post -1.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Marinus Pharmaceuticals by 5.0% in the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock worth $25,366,000 after purchasing an additional 132,689 shares in the last quarter. Avoro Capital Advisors LLC raised its position in shares of Marinus Pharmaceuticals by 31.4% in the first quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock valued at $37,431,000 after buying an additional 990,607 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in shares of Marinus Pharmaceuticals in the first quarter valued at approximately $384,000. SG Americas Securities LLC acquired a new stake in Marinus Pharmaceuticals during the second quarter worth approximately $34,000. Finally, Values First Advisors Inc. increased its stake in Marinus Pharmaceuticals by 501.8% during the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 52,257 shares during the period. Institutional investors and hedge funds own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.